Member Info for doggo

FFWD will be one of those stocks that never jumps pre news as there won’t be a discount retail placing that will be ramped and there isn’t a large enough core group of LTH.

It’s going to be one of those that will gap up massively and no one not holding will get in when the monetising news occurs.

When IMG meet their asking price you’ll see a sudden massive surge as those who’ve spotted the news buy all the available stock instantly, the general market won’t react as they won’t know what’s about to hit, RNS lands and it’s game over for non-holders.

The shame and regret will be for those who’ve held long who aren’t holding at that time, when it was clear it was always going to happen.

If you are selling at 6.3p then you are valuing Leap at what price?

They had an opening bid of £4.5m in 2017, 6 months prior to IMG buying in, and a full 2 years before IMG created IMG Arena and 28 months before IMG announced Leap had created an Official ATP tennis and USPGA golf.

It’s worth multiples now.

When they launch the Official ATP ATP tennis and Official Golf that’s when we will be laughing in here.

Personally I’d keep your eyes peeled for more Official games from them. Have a look at what sports licences they hold is the clue.

I don’t see anything negative from Wadnob, so either he’s selling at a loss (he isn’t stupid) or he’s holding.

You aren’t a SH so don’t know why you post negatively...hmm

I’ve no idea what you are chatting about Longlad. Gibberish

It’s a social commerce platform company, specifically It’s a CBD & Hemp lifestyle/wellness business that’s going to use Yooya’s platform to convert content consumers into e-commerce buyers, targeting the Asian market specifically.

Very logical step when you have Socati (hemp) and Emmac (CBD) as leaders in the US & Europe. Expect to see their wellness products being sold into the above markets.

A very exciting move for FFWD especially holding a significant ~8%.

Wellness and CBD/hemp target areas such as joint flexibility, cartilage health, cardiovascular function, circulatory system, immune system health, stress, skin-care/beauty and of course sleeping.

The RNS was particularly badly written as it didn’t tell the market what the main product was.

Why anyone who’s held FFWD for any length of time was surprised by the standard of the RNS is beyond me.

It’s very good news for holders and obviously shows the direction that FFWD are clearly heading (CBD, Hemp medical & wellness focused).

Makes me laugh from time to time.

7 am

Well it feels very much like the sellers have presented a TR1 present. Cheers

Latest released this Friday

You don’t let a business go global (which Leap now is) and share it all with an aim tinpot who hold the major holding of 44% and use all the official licensing that IMG hold.

That’s not aimed just at O’Donnell. I’ll be calling everyone out who wastes time posting anything other than PF news and opinion.

Needs to shut up and concentrate on news. O’Donnell etc you are all obsessed with the current Sp as it’s all you talk about. You’ve no interest in the PF companies so you just get in the way of any information being read.

Now share the same London address
https://twitter.com/greenhamneggs/status/1251967772684402688?s=21

ATP Tennis is pivoting during the coronavirus crisis with the launch of its first virtual sports product. Developed in collaboration with IMG ARENA, the product aims to provide a ‘fan-first’, authentic experience.

The feature is branded as ‘ATP 1000 Virtual Tennis’. IMG ARENA will begin rolling it out to partnered sportsbooks from the beginning of this month.

“A landmark agreement”

At a time when almost every major sporting event is on hold, virtual sports offers operators an opportunity to pivot. Often, this kind of market is just an ‘on the side’ nicety.

ATP Media CEO Mark Webster hailed the launch of ATP 1000 Virtual Tennis as a means of delivering entertainment to players. He also feels that it will aid global growth.

Webster’s thoughts are below.

“This is a landmark agreement for ATP Media at a challenging time. We are excited to be working with IMG ARENA to deliver fans around the world innovative content and new ways to enjoy their favourite tennis tournaments.

“Together we are creating a compelling, always-on product that will boost and diversify our sports betting offering while helping to continue to further develop our international footprint.”

Extending its virtual sporting portfolio

IMG ARENA, owned by the sports publishing group IMG, already has a broad collection of virtual sports. These include basketball, football, golf and horse racing.

Freddie Long, Managing Director of IMG ARENA, expressed his delight at adding tennis to the mix. His words were as follows.

“ATP Media are one of the most progressive and forward-thinking media companies – we are delighted to partner with them to launch the world’s first officially branded virtual tennis product.

“When we invested in virtual sports specialists Leap Gaming, our vision was to create official products and unlock new revenue streams and forms of fan engagement for our clients. ATP Media share this vision and desire to evolve the way that its fans could connect with tennis.

“The result is a game-changing product that maximises player engagement and operator returns. As with all of our virtual sports offerings, we have developed the most realistic look, feel, and betting experience.”

Instant football has increased 1800% since release. That’s huge growth

So why was yesterday so significant?

Reading the Portage RNS...you’ll come across this

Intensity Therapeutics announced yesterday it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY). The program will evaluate the safety and efficacy of Intensity’s lead product INT230-6, an investigational, novel and potent anti-cancer drug designed to directly kill cancer cells through intratumoral injection and improve immune cell recognition of cancer, when dosed in combination with Bristol Myers Squibb’s Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) immune checkpoint
inhibitor Yervoy®

Yervoy® is the brand name of the drug ipilimumab.
Remember those 2 names....

So let’s now go to the Portage 3 strong management team and look at their CVs

They all held very high positions within Bristol Myers here is a brief extract from each..

Ian Walters CEO he was a core member of Bristol-Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations, and the company’s immuno-oncology strategy.

Robert Kramer Chief Scientific Officer, he has been responsible for enabling the transition of 35 drugs from discovery into the clinic. Robert championed immunotherapy at Bristol-Myers Squibb, resulting in the acquisition of Medarex, Inc. in 2009 and its portfolio of immune therapeutics that included Ipilimumab (remember my name) and Nivolumab (Opdivo).

Steve Innaimo VP he previously spent 23 years at Bristol-Myers Squibb in roles of increasing responsibility including Senior Director of Oncology Project Management and Clinical Operations, having responsibility across the BMS portfolio ranging from discovery to life cycle management. During his time at BMS, Steve directly managed or provided development oversight for a number of the BMS immune-oncology assets, including Yervoy (remember my name) and Opdivo. He has driven multiple therapies to initial and post-marketing registrations globally.

Did they not read the RNS

Sold to early lol